Alcon Inc (STU:2U3)
€ 54.41 0 (0%) Market Cap: 40.55 Bil Enterprise Value: 44.04 Bil PE Ratio: 39.39 PB Ratio: 2.03 GF Score: 79/100

Alcon AG at Bank of America Merrill Lynch Health Care Conference Transcript

May 14, 2019 / 06:20PM GMT
Release Date Price: €53.57 (-3.53%)
Bob Hopkins
BofA Merrill Lynch - Analyst

So thanks, everybody, for being here. I am Bob Hopkins from Bank of America. This is the first session from a medical device perspective, so we are absolutely thrilled to have the senior management team from Alcon here today. Obviously I'd say newly traded, but it's really new for the third time back to the public markets for Alcon. And really from my perspective the feature presentation for me from a medtech perspective.

So we have a full team from the Company. Obviously Dave Endicott, the Company's CEO is here. Karen King, who is the Senior Vice President of Investor Relations and Communications, is here as well. And then Tim Stonesifer, the new Chief Financial Officer, is here as well.

And I should also give a shout out and thank you to Christina who works on Karen's team. A phenomenal set of resources that Alcon has developed for investors; definitely encourage everybody to take advantage of that great resource that's been created. So thank you, you guys, for being here.

So I wanted to -- in our time here today, to try and cover a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot